Cart
sales@molnova.com
E6446 dihydrochloride
CAS No. 1345675-25-3
E6446 dihydrochloride( —— )
Catalog No. M17250 CAS No. 1345675-25-3
E6446 dihydrochloride is a novel synthetic antagonist for nucleic acid-sensing TLRs; potently suppressed DNA stimulation of HEK:TLR9 cells with IC50 of 10 nM.
Purity : >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
| Size | Price / USD | Stock | Quantity |
| 1 mL x 10 mM in DMSO | 236 | In Stock |
|
| 2MG | 123 | In Stock |
|
| 5MG | 205 | In Stock |
|
| 10MG | 321 | In Stock |
|
| 25MG | 619 | In Stock |
|
| 50MG | 877 | In Stock |
|
| 100MG | 1190 | In Stock |
|
| 200MG | 1600 | In Stock |
|
| 500MG | Get Quote | In Stock |
|
| 1G | Get Quote | In Stock |
|
Biological Information
-
Product NameE6446 dihydrochloride
-
NoteResearch use only, not for human use.
-
Brief DescriptionE6446 dihydrochloride is a novel synthetic antagonist for nucleic acid-sensing TLRs; potently suppressed DNA stimulation of HEK:TLR9 cells with IC50 of 10 nM.
-
DescriptionE6446 dihydrochloride is a novel synthetic antagonist for nucleic acid-sensing TLRs; potently suppressed DNA stimulation of HEK:TLR9 cells with IC50 of 10 nM.
-
In Vitro——
-
In Vivo——
-
Synonyms——
-
PathwayMAPK/ERK Signaling
-
Targetp38 MAPK
-
RecptorTLR
-
Research AreaInflammation/Immunology
-
Indication——
Chemical Information
-
CAS Number1345675-25-3
-
Formula Weight522.51
-
Molecular FormulaC27H37Cl2N3O3
-
Purity>98% (HPLC)
-
SolubilityIn Vitro:?DMSO : 7.6 mg/mL (14.55 mM)
-
SMILESc1(c2ccc(OCCCN3CCCC3)cc2)nc2ccc(OCCCN3CCCC3)cc2o1.Cl.Cl
-
Chemical Name——
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
1. Lamphier M, et al. Novel small molecule inhibitors of TLR7 and TLR9: mechanism of action and efficacy in vivo. Mol Pharmacol. 2014 Mar;85(3):429-40.
molnova catalog
related products
-
MW181
MW181 (MW01-10-181SRM) is an isoform-selective, brain-permeable, and orally bioavailable small molecule inhibitor of p38α MAPK with Ki of 184 nM.
-
Losmapimod
Losmapimod (GSK-AHAB, GW856553X, SB856553)?is a selective, potent, orally active p38 MAPK inhibitor with pKi of 8.1 and 7.6 for p38α and p38β, respectively.
-
LY2228820 dimesylate
LY2228820 dimesylate (Ralimetinib) is a potent, selective, orally available inhibitor p38 MAPK with IC50 of 5.3 and 3.2 nM for p38α and p38β, respectively.
